Most Recent
Generic drug company Alphapharm has lost a bid for documents it claimed would show Sanofi-Aventis suspected as early as 2015 that patents for one of its injector pens may be invalid.
Generic drug maker Dr Reddy's Laboratories has reached a settlement with US-based Millennium Pharmaceuticals, agreeing to be restrained from selling a cheap version of cancer drug Velcade in Australia.
Prime Minister Scott Morrison has announced a royal commission into the aged care sector, saying he was moved to action by the "very disturbing trend" of non-compliance, abuse and failures in the industry.
The consumer regulator asked a court Friday to dismiss a lawsuit brought against it by Chinese vitamin giant Nature's Care Manufacture over Australian-made product labels, saying it had been wrongly "dragged into a controversy".
The defendants in a shareholder class action over QRxPharma's alleged failure to disclose problems with regulatory approval for its painkiller Moxduo have won access to information on class members' financial brokers.
Animal drug giant Merial is pushing on with its opposition to rival Intervet's bid to a patent a non-drug resistant injectable formula for treating animal parasites, filing an appeal in the Federal Court after it came up short in its challenge before IP Australia.
A court has struck out defamation claims brought by embattled Quintis founder Frank Wilson against the company's former directors over ASX statements he alleges suggested he knew about the company's termination of a supply contract with Nestle's dermatology unit, Galderma Laboratories.
Mercy Hospital for Women in Melbourne can give a pregnant 17-year-old Jehovah's witness a blood transfusion if her life is at risk during or after childbirth, a judge has found, despite the girl's refusal to consent on religious grounds.
ObjectiVision has presented a "limited" and "debatable" case that its source code for a glaucoma testing device was copied, the Federal Court heard Thursday as the trial in a four-year spat with the University of Sydney over IP rights came to a close.
TPI Enterprises has gone on the offensive in a patent lawsuit initiated by rival poppy processor Tasmanian Alkaloids, saying the patents at the centre of the suit describe natural parts that can't be patented.